Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy
Sponsor: Addpharma Inc.
Summary
The purpose of this study is to evaluate the efficacy and safety of AD-233A, AD-233B, AD-233C and/or AD-233D combination therapy
Official title: A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy in Patients With Type 2 Diabetes Mellitus
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
354
Start Date
2026-09-30
Completion Date
2028-06-30
Last Updated
2026-09-16
Healthy Volunteers
No
Conditions
Interventions
AD-233A
PO, Once daily(QD), 24 weeks
AD-233B
PO, Once daily(QD), 24 weeks
AD-233C
PO, Once daily(QD), 24 weeks
AD-233D
PO, Once daily(QD), 24 weeks
AD-233A Placebo
PO, Once daily(QD), 24 weeks
AD-233B Placebo
PO, Once daily(QD), 24 weeks